Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

Clinical trial NCT06897046 · RECRUITING

Trial details

NCT number: NCT06897046
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer (NSCLC)II-IIIB

Start date: 2025-07-30
Primary completion: 2027-02-25
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.